Repositori institucional URV
Español Català English
TITLE:
Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population - imarina:575110

URV's Author/s:López Dupla, Jesús Miguel / Vidal Marsal, Francisco
Author, as appears in the article.:Murcia, JM; González-Comeche, J; Marín, A; Barberán, J; Granizo, JJ; Aguilar, L; González-Moreno, J; González-Pina, B; López-Dupla, M; Irurzun, J
Author's mail:jesusmiguel.lopez@urv.cat
francesc.vidal@urv.cat
Author identifier:0000-0002-9141-2523
0000-0002-6692-6186
Journal publication year:2009
Publication Type:Journal Publications
ISSN:1198743X
APA:Murcia, JM; González-Comeche, J; Marín, A; Barberán, J; Granizo, JJ; Aguilar, L; González-Moreno, J; González-Pina, B; López-Dupla, M; Irurzun, J (2009). Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population. Clinical Microbiology And Infection, 15(11), 1046-1050. DOI: 10.1111/j.1469-0691.2009.02843.x
Papper original source:Clinical Microbiology And Infection. 15 (11): 1046-1050
Abstract:To evaluate in routine hospital practice the clinical response to ertapenem in comparison with other parenteral antibiotics in the treatment of community-acquired pneumonia (CAP), clinical records from patients with severe CAP treated with ertapenem from July 2002 to June 2006 in seven Spanish hospitals were retrospectively reviewed. Patients were classified according to the Pneumonia Severity Index (PSI). Each ertapenem-treated patient was matched with two patients in the same hospital treated with other antibiotics, according to age (difference 76 years). Comorbidities were present in 193 patients (95.5%). No differences were found in median hospital stay (7 days for ertapenem vs. 10 days for comparators, p 0.066). A slightly higher clinical response rate was obtained for ertapenem vs. comparators (88.7% vs. 77.1%; p 0.0465; OR 2.25; 95% CI 0.99-5.12), with significant differences in clinical response in patients coming from nursing homes (95.8% ertapenem vs. 63.8% comparators; p 0.0034) but not in non-institutionalized patients (85.4% ertapenem vs. 84.5% comparators; p 0.929). The higher clinical response to ertapenem vs. comparators in severe CAP was due to its significantly higher efficacy in healthcare-associated CAP in patients coming from nursing homes.
Article's DOI:10.1111/j.1469-0691.2009.02843.x
Link to the original source:https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(14)61801-2/fulltext
Papper version:info:eu-repo/semantics/submittedVersion
licence for use:https://creativecommons.org/licenses/by/3.0/es/
Department:Medicina i Cirurgia
Licence document URL:https://repositori.urv.cat/ca/proteccio-de-dades/
Thematic Areas:Saúde coletiva
Química
Odontología
Microbiology (medical)
Microbiology
Medicine (miscellaneous)
Medicina veterinaria
Medicina iii
Medicina ii
Medicina i
Interdisciplinar
Infectious diseases
Farmacia
Ciências biológicas iii
Ciências biológicas ii
Ciências biológicas i
Ciências ambientais
Ciências agrárias i
Biotecnología
Astronomia / física
Keywords:Therapy
Retrospective study
Nursing homes
Necrosis-factor-alpha
Monoclonal-antibody
Hospital practice
Guidelines
Gamma-interferon
Ertapenem
Elderly
Ceftriaxone
Cap
Adults
Entity:Universitat Rovira i Virgili
Record's date:2024-02-10
Search your record at:

Available files
FileDescriptionFormat
DocumentPrincipalDocumentPrincipalapplication/pdf

Information

© 2011 Universitat Rovira i Virgili